

# Curriculum Vitae

(Last updated: 2023-01-12)

Hee Seung Lee, MD, PhD

## Education and Training

2001.3 ~ 2007.2, Yonsei University College of Medicine, Korea

2007.3 ~ 2008.2, Internship, Yonsei University Health System, Seoul, Korea

2011.3 ~ 2015.2, Residency in Internal Medicine. Severance Hospital, Yonsei University Health System, Seoul, Korea

2015.3 ~ 2016.2, Fellowship, Yonsei University Health System, Seoul, Korea

2016.3 ~ 2018.2, Clinical research assistant professor

2018.3 ~ Present, Clinical assistant professor

## Professional Experience

2019.6 Visiting researcher, The Gurdon institute, Wellcome Trust/Cancer Research UK Gurdon Institute  
University of Cambridge

2022.9 Visiting professor. Indiana university, Gastroenterology department

## Prizes and Awards

2015 Multi-national Alliant Gastro-Intestinal Cancer Symposium (MAGICS), best poster presentation award

2016 Korea Digestive Disease Week (KDDW), best poster presentation award

2016 Seoul International Digestive Disease Symposium (SIDDS), Young investigator award

2017 Yonsei University College of Medicine, Doctoral Excellence Award

2018 Asian Pacific Digestive Week (APDW), Rising star award, Pancreatobiliary department

2019 Korean pancreatobiliary association, best oral presentation award

2020 Korean Society of GI cancer research, best oral presentation award (PI)

2021 Korean Society of GI cancer research, best oral presentation award (PI)

2022 Korea Digestive Disease Week (KDDW), best poster presentation award

## Publications

-A novel HDAC inhibitor, CG200745, inhibits pancreatic cancer cell growth and overcomes gemcitabine resistance, Scientific reports. 2017, 7:416151, 1st author

-Postoperative adjuvant chemotherapy is associated with a lower incidence of colorectal adenomas in patients with previous colorectal cancer. Gastrointest Endoscopy. 2017, Apr 18, 1st author

-Combined use of CEMIP and CA 19-9 enhances diagnostic accuracy for pancreatic cancer. Scientific reports.

2018 Feb 21; 8(1):3383. 1st author

-Establishment of pancreatic cancer cell lines with endoscopic ultrasound-guided biopsy via conditionally reprogrammed cell culture. *Cancer medicine*. 2019, 1st author

-A Variant of SLC1A5 Is a Mitochondrial Glutamine Transporter for Metabolic Reprogramming in Cancer Cells, *Cell metabolism*, 2020, co-author

-Serum Dickkopf-1 in Combined with CA 19-9 as a Biomarker of Intrahepatic Cholangiocarcinoma Cancers, 2021, 1st author

-Usefulness of Smartphone Applications for Improving Nutritional Status of Pancreatic Cancer Patients: Randomized Controlled Trial. *JMIR mHealth and uHealth*, 2021, Corresponding author

-Profiling of conditionally reprogrammed cell lines for in vitro chemotherapy response prediction of pancreatic cancer, *EBioMedicine*, 2021, 1st author

-Gemcitabine plus Nab-paclitaxel as a second-line treatment following FOLFIRINOX failure in advanced pancreatic cancer: a multicenter, single-arm, open-label, phase 2 trial. *Therapeutic advances in medical oncology*, 2021, 1st author

-BRCA 1/2 Germline Mutation Predicts the Treatment Response of FOLFIRINOX with Pancreatic Ductal Adenocarcinoma in Korean Patients. *Cancers*. 2022, Corresponding author

-Integrative analysis of multiple genomic data from intrahepatic cholangiocarcinoma organoids enables tumor subtyping, *Nature communications*, 2023, accepted, 1st author

-Enhanced glutaminolysis drives hypoxia-induced chemoresistance in pancreatic cancer, *Cancer search*, 2023, accepted, co-author

-Difference of risk of pancreatic cancer in new-onset diabetes and long-standing diabetes: population-based cohort study, *The Journal of Clinical Endocrinology & Metabolism*, 2023, 1st author

-Plasmon-enhanced single extracellular vesicle analysis for cholangiocarcinoma diagnosis, *Advanced Science*. 2023, accepted, co-author